BASS1 Antibody

What is BASP1 and why is it significant in research?

BASP1 (Brain Acid Soluble Protein 1), also known as NAP-22 (22 kDa neuronal tissue-enriched acidic protein) or Neuronal axonal membrane protein NAP-22, is a transcriptional cosuppressor belonging to the BASP1 family of proteins . It is predominantly expressed in neurons, renal podocytes, and spermatids . BASP1 is significant in research due to its roles in neuronal development, transcriptional regulation, and potential involvement in cancer pathways. Antibodies against BASP1 are essential tools for studying its expression, localization, and function in various cellular contexts.

What are the known molecular characteristics of BASP1 protein?

BASP1 has a predicted molecular weight of 23 kDa, but displays unique molecular behavior in experimental settings. The protein forms oligomers in SDS, ranging from 30-150 kDa . At least two forms exist in humans: one 48-52 kDa form and another 32-40 kDa form, which are not functionally equivalent . BASP1 can undergo SUMOylation, which adds approximately 20 kDa to its apparent molecular weight . Additionally, N-terminal fragments called BIRPs (BASP1-Immunoreactive Proteins) run from 30-50 kDa in 12% acidic SDS-PAGE . Interestingly, varying concentrations of SDS will change the apparent BASP1 molecular weight from 56 kDa in 8% SDS-PAGE to 41 kDa in 13% SDS-PAGE .

What cell types and tissues typically express BASP1?

BASP1 expression is primarily detected in neurons, where it was first characterized, but is also expressed in renal podocytes and spermatids . In experimental contexts, BASP1 has been detected in various cell lines including HeLa human cervical epithelial carcinoma cells and DU145 human prostate carcinoma cells . The varied expression pattern suggests diverse functional roles across different tissues and cell types.

What types of BASP1 antibodies are available for research?

Several types of BASP1 antibodies are available for research applications, including:

• Polyclonal antibodies: Such as human BASP1 antigen affinity-purified polyclonal antibodies

• Monoclonal antibodies: Including rabbit recombinant monoclonal BASP1 antibodies

• Species-specific antibodies: Both human-specific and cross-reactive antibodies with varying epitope targets

The selection of antibody type should be based on the specific research application, required specificity, and experimental design.

What applications are BASP1 antibodies suitable for?

BASP1 antibodies have been validated for multiple research applications:

• Western blotting (WB): For detecting BASP1 protein in cell and tissue lysates

• Immunohistochemistry with paraffin-embedded sections (IHC-P): For localizing BASP1 in tissue specimens

• Immunoprecipitation (IP): For isolating BASP1 protein complexes

• Immunocytochemistry/Immunofluorescence (ICC/IF): For cellular localization studies

• Flow cytometry (intracellular): For quantifying BASP1 expression in cell populations

Each application may require optimization of antibody concentration and experimental conditions.

How should researchers validate a BASP1 antibody?

Validation of BASP1 antibodies should include:

• Positive controls: Testing with samples known to express BASP1 (e.g., HeLa or DU145 cell lines)

• Negative controls: Using samples with low or no BASP1 expression

• Peptide competition assays: To confirm specificity for the target epitope

• Knockout/knockdown validation: Using BASP1 knockout or knockdown samples

• Multiple detection methods: Validating across different applications (e.g., WB, IHC, IF)

• Multiple antibodies: Using antibodies targeting different epitopes to confirm results

Given BASP1's complex molecular behavior, particular attention should be paid to band patterns in Western blots.

Why does BASP1 show multiple bands on Western blots, and how should researchers interpret these results?

BASP1 typically shows multiple bands on Western blots due to several factors:

• Oligomerization: BASP1 forms oligomers in SDS, ranging from 30-150 kDa

• Multiple isoforms: At least two forms exist in humans (48-52 kDa and 32-40 kDa)

• Post-translational modifications: SUMOylation adds approximately 20 kDa to its apparent molecular weight

• N-terminal fragments (BIRPs): These run from 30-50 kDa in 12% acidic SDS-PAGE

• SDS concentration effects: The apparent molecular weight varies from 56 kDa in 8% SDS-PAGE to 41 kDa in 13% SDS-PAGE

When interpreting Western blot results:

• Expect multiple bands rather than a single band at 23 kDa

• The ~60 kDa band may represent SUMOylated BASP1

• Lower molecular weight bands may represent different isoforms or fragments

• Consider using gradient gels to better resolve the multiple forms

What are the optimal conditions for Western blotting with BASP1 antibodies?

For optimal Western blotting with BASP1 antibodies:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • Include phosphatase inhibitors if studying phosphorylated forms

  • Consider using SUMO protease inhibitors if studying SUMOylated forms

• Gel selection:

  • 4-20% gradient SDS-PAGE gels are recommended to resolve multiple BASP1 forms

  • Consider the effect of SDS concentration on apparent molecular weight

• Transfer conditions:

  • Optimize transfer time and voltage for efficient transfer of all molecular weight forms

• Antibody concentration:

  • Approximately 1 μg/mL has been reported as effective for human BASP1 antigen affinity-purified polyclonal antibody

  • Optimal dilutions should be determined empirically for each application

• Detection:

  • Use appropriate secondary antibodies (e.g., HRP-conjugated Anti-Sheep IgG Secondary Antibody has been used with sheep polyclonal antibodies)

How can BASP1 antibodies be effectively used in immunohistochemistry?

For effective immunohistochemistry with BASP1 antibodies:

• Sample preparation:

  • Use appropriate fixation (typically formalin fixation and paraffin embedding)

  • Consider antigen retrieval methods to expose epitopes

• Blocking:

  • Use appropriate blocking solutions to minimize background staining

  • Include steps to block endogenous peroxidase activity

• Antibody incubation:

  • Optimize antibody concentration and incubation time

  • Consider overnight incubation at 4°C for maximal sensitivity

• Controls:

  • Include positive control tissues (brain sections, kidney podocytes)

  • Include negative controls (isotype control or primary antibody omission)

• Detection system:

  • Choose appropriate detection systems (e.g., DAB for chromogenic detection)

  • Consider signal amplification for low-abundance targets

• Interpretation:

  • BASP1 may show both nuclear and cytoplasmic localization depending on the cell type

How can researchers distinguish between different isoforms of BASP1 using antibodies?

Distinguishing between different BASP1 isoforms requires strategic approaches:

• Epitope-specific antibodies:

  • Use antibodies targeting specific regions unique to certain isoforms

  • Consider custom antibody development for isoform-specific epitopes

• Size-based separation:

  • Use appropriate percentage SDS-PAGE gels to resolve the 48-52 kDa and 32-40 kDa forms

  • Consider 2D gel electrophoresis to separate based on both size and charge

• Charge-based discrimination:

  • The 55-kDa component has been reported to have an acidic pI of approximately 4.0 with considerable charge heterogeneity

  • The 45-kDa component has a more neutral pI of approximately 7.5

• Isoform enrichment:

  • Consider subcellular fractionation to enrich for specific isoforms

  • Immunoprecipitation with isoform-specific antibodies

• Mass spectrometry:

  • Follow immunoprecipitation with mass spectrometry to identify specific isoforms

  • Look for post-translational modifications that distinguish isoforms

How does SUMOylation of BASP1 impact antibody recognition?

SUMOylation of BASP1 adds approximately 20 kDa to its apparent molecular weight , which can affect antibody binding and experimental outcomes in several ways:

• Epitope masking:

  • SUMOylation may mask certain epitopes, reducing antibody binding

  • Antibodies targeting regions near SUMOylation sites may show differential binding to modified vs. unmodified BASP1

• Detection strategies:

  • When studying SUMOylated BASP1, look for a band approximately 20 kDa larger than unmodified forms

  • Consider using anti-SUMO antibodies in parallel to confirm SUMOylated forms

• Experimental considerations:

  • Include SUMO protease inhibitors in lysis buffers to preserve SUMOylated forms

  • Consider deSUMOylation assays to confirm identity of higher molecular weight bands

• Functional studies:

  • Different antibodies may be required to study the functional differences between SUMOylated and non-SUMOylated BASP1

What are the considerations for using BASP1 antibodies in co-immunoprecipitation experiments?

When using BASP1 antibodies for co-immunoprecipitation (co-IP) experiments:

• Antibody selection:

  • Choose antibodies validated for immunoprecipitation applications

  • Consider the epitope location relative to potential interaction sites

• Lysis conditions:

  • Use non-denaturing lysis buffers to preserve protein-protein interactions

  • Include appropriate protease and phosphatase inhibitors

• Pre-clearing:

  • Pre-clear lysates to reduce non-specific binding

  • Use appropriate control IgG matched to the host species of the BASP1 antibody

• Binding conditions:

  • Optimize antibody amount and incubation conditions

  • Consider whether to pre-bind antibody to beads or directly to lysate

• Washing stringency:

  • Balance between removing non-specific interactions and preserving specific ones

  • Consider detergent concentration and salt concentration in wash buffers

• Elution and detection:

  • Use appropriate elution conditions that don't interfere with downstream applications

  • Consider both the BASP1 and potential interacting partners when designing detection methods

What are common challenges when using BASP1 antibodies in Western blotting?

Common challenges with BASP1 antibodies in Western blotting include:

• Multiple band patterns:

  • BASP1 naturally shows multiple bands due to oligomerization, different isoforms, and post-translational modifications

  • Solution: Use positive controls with known BASP1 expression patterns for comparison

• Unexpected molecular weights:

  • BASP1's apparent molecular weight varies with SDS concentration and gel percentage

  • Solution: Use gradient gels (4-20%) and standardize SDS concentration

• Background issues:

  • High background can obscure specific BASP1 bands

  • Solution: Optimize blocking conditions, antibody dilutions, and washing steps

• Variability between antibodies:

  • Different antibodies may recognize different forms of BASP1

  • Solution: Validate results with multiple antibodies targeting different epitopes

• Sample degradation:

  • BASP1 may be susceptible to proteolytic degradation

  • Solution: Use fresh samples with complete protease inhibitor cocktails

How can researchers optimize immunofluorescence protocols for BASP1 detection?

For optimal immunofluorescence detection of BASP1:

• Fixation:

  • Compare different fixation methods (paraformaldehyde, methanol, acetone)

  • Optimize fixation time to balance antigen preservation and accessibility

• Permeabilization:

  • Test different permeabilization agents (Triton X-100, saponin, digitonin)

  • Adjust concentration and incubation time for optimal results

• Blocking:

  • Use appropriate blocking agents (BSA, normal serum, commercial blocking buffers)

  • Include longer blocking times to reduce background

• Antibody concentration:

  • Titrate primary antibody to determine optimal concentration

  • Consider longer incubation times at lower concentrations

• Controls:

  • Include positive control cells with known BASP1 expression

  • Use appropriate negative controls (primary antibody omission, isotype control, blocking peptide)

• Signal detection:

  • Select appropriate fluorophores based on expression level and imaging equipment

  • Consider signal amplification methods for low-abundance detection

• Counterstaining:

  • Use DAPI for nuclear counterstaining

  • Consider co-staining with subcellular markers to assess localization

What control samples should be included when working with BASP1 antibodies?

When working with BASP1 antibodies, include the following controls:

• Positive controls:

  • Cell lines with confirmed BASP1 expression (e.g., HeLa, DU145)

  • Brain tissue sections (neurons express BASP1)

  • Kidney tissue sections (podocytes express BASP1)

• Negative controls:

  • Cell lines with low or no BASP1 expression

  • Primary antibody omission controls

  • Isotype controls matched to the primary antibody

• Specificity controls:

  • Blocking peptide competition assays

  • BASP1 knockdown or knockout samples if available

  • Recombinant BASP1 protein as a reference standard

• Loading controls:

  • Appropriate housekeeping proteins for Western blotting

  • Cellular markers for localization studies in IF/IHC

• Process controls:

  • Secondary antibody-only controls to assess non-specific binding

  • Cross-reactivity controls if working with multiple species